A man at one of my support groups asked if I could go back in time would I repeat my journey with cancer? I first thought was this a stupid question; of course, I would not. Why would I want to repeat this experience? Who in their right mind would elect to again walk on [...]
A confirmatory study evaluating the prognostic value of C-reactive protein (CRP) levels in men with castrate-resistant prostate cancer (CRPC) was presented at the 2009 American Society of Clinical Oncology (ASCO) conference in Orlando Florida. Historically, CRP has been associated with adverse outcomes in men with CRPC treated with docetaxel. This study, presented by R. Prins, [...]
It is inevitable; most men with prostate cancer, who require treatment with androgen deprivation therapy (ADT), will eventually become resistance to treatment leading to the development of metastatic disease. Men who develop metastatic castrate-resistant disease have a very poor prognosis. Historically, their overall survival is estimated only to be 24 to 36 months. A study [...]
The use of Docetaxel (chemotherapy) extends survival time in men with castration-resistant prostate cancer (CRPC). Many researchers believe that platinum compounds, particularly Carboplatin, when added to docetaxel (taxane-based chemotherapy) can further extend survival times. A study at the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Investigated the efficacy [...]
The absence of a stromal protein called caveolin-1 appears to be a marker for advanced prostate cancer and for metastasis, researchers from the Kimmel Cancer Center at Jefferson and Harvard Medical School reported in "Cell Cycle." Caveolin-1 has already been shown to be a good biomarker serving as a prognostic factor for breast cancer. The [...]